Azadirachtin B is an limonoid isolated from seed kernels of Azadirachta indica . Azadirachtin B increases alkaline phosphatase (ALP) activity and stimulates osteoblast differentiation. Azadirachtin B is active against the Epstein-Barr virus early antigen (EBV-EA) . Azadirachtin B has insecticidal, nematocidal, anticancer, anti-inflammatory, antiviral and osteogenic properties
In Vitro
Azadirachtin B (1 pM-100 µM; 48 hours; Osteoblast cells) treatment shows highest proliferation at 10 nM and 100 pM concentrations in osteoblast cells. Azadirachtin B increases expression of RunX-2 ∼2.5 fold at 10 nM concentration, ALP expression ∼2.8 fold at 10 nM and 100 pM concentration and OCN expression ∼2.5 folds at 10 nM as compared with control. Azadirachtin B (Compound 4) exhibits toxicity to the diamondback moth ( Plutella xylostella ) with an LD 50 of 4.85-1.06 µg/g body weight, in 92 h. Azadirachtin B (compound 21) exhibits moderate or potent inhibitory effects (IC50 value of 384 mol ratio/32 pmol TPA) against the Epstein-Barr virus early antigen (EBV-EA) activation induced by tetradecanoylphorbol-13-acetate (TPA). MCE has not independently confirmed the accuracy of these methods. They are for reference only. Cell Proliferation AssayCell Line: Osteoblast cells Concentration: 1 pM, 100 pM, 10 nM, 1 µM, 100 µM Incubation Time: 48 hours Result: Showed highest proliferation at 10 nM and 100 pM concentrations in osteoblast cells.
In Vivo
On evaluation of Azadirachtin B (compound 21; oral administration) for its anti-tumor-initiating activity on the two-stage carcinogenesis of mouse skin tumor induced by peroxynitrite (ONOO-; PN) as an initiator and TPA as a promoter, this exhibited marked inhibitory activity. MCE has not independently confirmed the accuracy of these methods. They are for reference only.
Form:Solid
IC50& Target:Plutella xylostella,Alkaline phosphatase (ALP),Epstein-Barr virus early antigen (EBV-EA)
